Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RAPT Therapeutics (RAPT) Income towards Parent Company: 2020-2023

Historic Income towards Parent Company for Therapeutics (RAPT) over the last 4 years, with Dec 2023 value amounting to -$33.2 million.

  • Therapeutics' Income towards Parent Company fell 35.96% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 48.10%. This contributed to the annual value of -$127.1 million for FY2023, which is 48.10% down from last year.
  • According to the latest figures from Q4 2023, Therapeutics' Income towards Parent Company is -$33.2 million, which was up 2.07% from -$33.9 million recorded in Q3 2023.
  • Therapeutics' Income towards Parent Company's 5-year high stood at -$12.4 million during Q2 2020, with a 5-year trough of -$33.9 million in Q3 2023.
  • For the 3-year period, Therapeutics' Income towards Parent Company averaged around -$23.5 million, with its median value being -$21.2 million (2022).
  • Data for Therapeutics' Income towards Parent Company shows a maximum YoY plummeted of 56.47% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Therapeutics' Income towards Parent Company stood at -$12.7 million in 2020, then slumped by 40.79% to -$17.9 million in 2021, then slumped by 36.27% to -$24.4 million in 2022, then crashed by 35.96% to -$33.2 million in 2023.
  • Its Income towards Parent Company was -$33.2 million in Q4 2023, compared to -$33.9 million in Q3 2023 and -$28.4 million in Q2 2023.